🇺🇸 FDA
Pipeline program

Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281

D0816C00025

Phase 1 small_molecule active

Quick answer

Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281 for solid tumors is a Phase 1 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
solid tumors
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials